Inherited atherogenic dyslipidemias: are they correctly reported?

Hegele RA. Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet 2009; 10: 109–121. 2009/01/14. DOI: 10.1038/nrg2481.

Ellis KL Hooper AJ Burnett JR , et al. Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. Nat Rev Endocrinol 2016; 12: 467–484. 2016/05/21. DOI: 10.1038/nrendo.2016.69.

Mach F Baigent C Catapano AL , et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111–188. 2019/09/11. DOI: 10.1093/eurheartj/ehz455.

Genest J Jr McNamara JR Ordovas JM , et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992; 19: 792–802. 1992/03/25. DOI: 10.1016/0735-1097(92)90520-w.

Ganda OP Bhatt DL Mason RP , et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol 2018; 72: 330–343. 2018/06/25. DOI: 10.1016/j.jacc.2018.04.061.

Cannon CP de Lemos JA Rosenson RS , et al. Getting to an imprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): methods and baseline data of a registry of high cardiovascular risk patients in the United States. Am Heart J 2020; 219: 70–77. 2019/11/15. DOI: 10.1016/j.ahj.2019.10.014.

Navar AM Wang TY Goldberg AC , et al. Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry. Am Heart J 2015; 170: 865–871. 2015/11/07. DOI: 10.1016/j.ahj.2015.08.002.

Cerra C Lottaroli S. Use of administrative databases for calculating the cost of chronic patologies. Pharmacoeconomics Italian Research Articles 2004; 6: 9.

Schiele F Gale CP Bonnefoy E , et al. Quality indicators for acute myocardial infarction: a position paper of the Acute Cardiovascular Care Association. Eur Heart J Acute Cardiovasc Care 2017; 6: 34–59. 2016/08/31. DOI: 10.1177/2048872616643053.

Nordestgaard BG Chapman MJ Humphries SE , et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34: 3478–3490a. 2013/08/21. DOI: 10.1093/eurheartj/eht273.

Macchi C Sirtori CR Corsini A , et al. A new dawn for managing dyslipidemias: the era of RNA-based therapies. Pharmacol Res 2019; 150: 104413. 2019/08/27. DOI: 10.1016/j.phrs.2019.104413.

Blom DJ Averna MR Meagher EA , et al. Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia. Circulation 2017; 136: 332–335. 2017/07/19. DOI: 10.1161/CIRCULATIONAHA.117.028208.

Macchi C Banach M Corsini A , et al. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents. Eur J Prev Cardiol 2019; 26: 930–949. 2019/02/20. DOI: 10.1177/2047487319831500.

Santos RD Stein EA Hovingh GK , et al. Long-term evolocumab in patients with familial hypercholesterolemia. J Am Coll Cardiol 2020; 75: 565–574. 2020/02/15. DOI: 10.1016/j.jacc.2019.12.020.